MedTrace Logo

Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension

NCT00795262 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2011-05-05

No results posted yet for this study

Summary

We will evaluate the combination of quinapril and alpha lipoic acid in patients with diabetes mellitus and hypertension. We will determine whether the combination of quinapril and lipoic acid as compared to quinapril and placebo provides benefit on systemic blood pressure and proteinuria.

Conditions

Interventions

DRUG

Quinapril (Accupril) plus Alpha Lipoic Acid

Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).

DRUG

accupril, placebo

accupril 40 mg

DRUG

accupril, alpha lipoic acid

accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg

Sponsors & Collaborators

  • InVasc Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Syed T. Rahman, MD · Atlanta Vascular Research Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00795262 on ClinicalTrials.gov